The Sentinel

THE OFFICIAL BLOG OF THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC).

President's Message – March 2017

As I write this message on International Women’s Day, I am honored to contribute to the Society for Immunotherapy of Cancer (SITC) as its first female President, hopefully paving the way for future women in science to do the same. Choosing a career in science has been extremely rewarding, especially as a Professor at the University of Pittsburgh Cancer Institute where women routinely serve as department chairs, program leaders and SPORE PIs.

My career path has not been without challenges – as my female colleagues would agree – navigating a male dominated field can be challenging at times. However, as more women progress through the field, there are more mentors from whom to learn, more formal leadership training sessions and more flexible work environments and tenure clocks. Observing a woman in a leadership position of any type sends a powerful message to women everywhere – next time it could be you.

As we all continue to move the field forward with our unique skills and talents, I encourage you to visit SITC's 32ndAnnual Meeting & Pre-Conference Programs (November 8-12, 2017) microsite which is now live for society members to register and secure housing. In addition, the call for abstracts period is now open for everyone. This is a great opportunity to showcase your latest research at the largest conference solely focused on cancer immunotherapy. It is going to be another outstanding meeting! www.sitcancer.org/2017

Finally, SITC’s Call for Comment on the “Consensus Statement on Immunotherapy for the Treatment of Bladder Carcinoma.” In line with other publications in SITC’s Cancer Immunotherapy Guidelines series, this Consensus Statement was developed by experts in the field and provides key indicators to help practicing oncologists determine when and how to use immunotherapy when treating patients with bladder cancer. Specifically, these guidelines focus on selecting patients for treatment, managing toxicities, determining clinical endpoints and guiding appropriate sequencing or combination of therapies in the setting of bladder cancer. We welcome participation from SITC members in the development of these guidelines. Provide your feedback on this important SITC initiative before the Open Comment period ends at 5 p.m. ET on Thursday, April 20, 2017.

Sincerely,

Dr-Butterfield_IM_Final.jpg









Lisa H. Butterfield, PhD

SITC President

No comments:

Post a Comment